Literature DB >> 21767121

Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting.

Zhi-xiang Yuan1, Jing-jing Li, Di Zhu, Xun Sun, Tao Gong, Zhi-rong Zhang.   

Abstract

PURPOSE: To investigate the influence of N-acetylation of chitosan on the renal targeting.
METHODS: Hydroxyethyl chitosans (HECs) with different N-acetylation degrees of 10.0%, 52.7%, and 81.8% (HECs-10, HECs-53, and HECs-82) were synthesized. Then, in vitro evaluations including cellular uptake and cytotoxicity were performed. Finally, tissue distribution of HECs in normal mice and megalin-shedding mice models were evaluated.
RESULTS: HECs-10 exhibited the highest binding affinity and uptake capacity to MDCK cells, expressing the megalin receptor. Additionally, cytotoxicity assay showed that there were no obvious effects of HECs on the viability of L929 and MDCK cells. Consistent with the cellular uptake study, it was shown in vivo study that all HECs exhibited renal-targeting profile. Especially, HECs-10 with low N-acetylation overwhelmingly accumulated in the kidneys, while urinary excretion of HECs-10 was low, in comparison with that of HECs-53 and HECs-82. Finally, the renal accumulation of HECs in megalin-shedding mice was dramatically reduced by over ~50% as compared with that in normal animals and the specific renal uptake of HECs was increasingly inhibited with the N-acetylation increased.
CONCLUSION: Inspired by these observations, we can conclude that decreasing the N-acetylation could enhance accumulation of low-molecular-weight chitosan in kidneys and amino groups in the structure could be essential for renal-targeting profile of chitosan.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767121     DOI: 10.3109/1061186X.2010.521158

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  7 in total

Review 1.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

2.  Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer.

Authors:  Ye Liang; Yonghua Wang; Liping Wang; Zhijuan Liang; Dan Li; Xiaoyu Xu; Yuanbin Chen; Xuecheng Yang; Hongbo Zhang; Haitao Niu
Journal:  Bioact Mater       Date:  2020-09-08

Review 3.  Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives.

Authors:  Bo Lin; Ying-Yu Ma; Jun-Wei Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-13

4.  Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.

Authors:  Shan Gao; San Hein; Frederik Dagnæs-Hansen; Kathrin Weyer; Chuanxu Yang; Rikke Nielsen; Erik I Christensen; Robert A Fenton; Jørgen Kjems
Journal:  Theranostics       Date:  2014-08-13       Impact factor: 11.556

5.  Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis.

Authors:  Chang Seong Kim; Ansuja Pulickal Mathew; Arathy Vasukutty; Saji Uthaman; Soo Yeon Joo; Eun Hui Bae; Seong Kwon Ma; In-Kyu Park; Soo Wan Kim
Journal:  J Nanobiotechnology       Date:  2021-04-17       Impact factor: 10.435

6.  Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies.

Authors:  Xia-kai He; Zhi-xiang Yuan; Xiao-juan Wu; Chao-qun Xu; Wan-yu Li
Journal:  Theranostics       Date:  2012-11-06       Impact factor: 11.556

Review 7.  Kidney-targeted drug delivery systems.

Authors:  Peng Zhou; Xun Sun; Zhirong Zhang
Journal:  Acta Pharm Sin B       Date:  2014-01-23       Impact factor: 11.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.